Home›Research›Compare›Angiotensin (1-7) vs Teriparatide
Peptide ComparisonAngiotensin (1-7) vs Teriparatide
Both are Longevity & Cellular peptides.
Angiotensin (1-7)
Ang-(1-7)
Half-life: ~9–10 sec (rat)
No providers listed yet
Teriparatide
Forteo
Half-life: ~1 hour
3 providers listed
Teriparatide is FDA-approved, while Angiotensin (1-7) is investigational — the clearest structural difference between them.
Angiotensin (1-7)
Evidence
Half-life
~9–10 sec (rat)
Teriparatide
Evidence
Half-life
~1 hour
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Teriparatide |
| Further along in FDA review | Teriparatide |
| Less frequent dosing (longer half-life) | Angiotensin (1-7) |
| More provider options (0 vs 3) | Teriparatide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Angiotensin (1-7)
Teriparatide
Angiotensin (1-7)
The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.
Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…
Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.
Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the re…
+11 more
Teriparatide
The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects…
Pharmacological Management of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living…
Association between antiosteoporosis medications and risk of sacral fracture after lumbosacral fusion in adul…
Consensus on the Treatment of Midshaft Clavicular Fractures in Collegiate Football Players: A Delphi Approach…
+3 more
About Angiotensin (1-7)
Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.
About Teriparatide
Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Angiotensin (1-7)
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Teriparatide
No established clinical contraindications
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Where to source these peptides
Angiotensin (1-7)
Browse directory →
Providers offeringTeriparatide
3 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.